Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Reduced Elafin Levels Associated with Celiac Disease Bowel Inflammation

By BiotechDaily International staff writers
Posted on 22 Apr 2014
Print article
Image: Biopsy of small bowel showing celiac disease manifested by blunting of villi, crypt hyperplasia, and lymphocyte infiltration of crypts (Photo courtesy of Wikimedia Commons).
Image: Biopsy of small bowel showing celiac disease manifested by blunting of villi, crypt hyperplasia, and lymphocyte infiltration of crypts (Photo courtesy of Wikimedia Commons).
Levels of the enzyme elafin, an endogenous serine protease inhibitor, were lower in the small intestinal epithelium of patients with active celiac disease (CD) as compared to similar tissue from control patients.

Celiac disease is an immune disorder that occurs in susceptible individuals when foods that contain gluten and its derivative, the highly immunogenic gliadin peptide, trigger an immune response that leads to destruction of the intestinal lining, abdominal pain, changes in bowel habits, malnutrition and other symptoms that include anemia and neurological problems.

Investigators at McMaster University (Hamilton, ON, Canada) used immunofluorescence techniques to examine the role of elafin in CD using tissues taken from human small intestines. The degree of deamidation of the 33-mer gliadin peptide was analyzed by liquid chromatography-mass spectrometry. To study the effects of elafin on a mouse model of celiac disease, the protein was delivered to the intestine of gluten-sensitive mice using a recombinant Lactococcus lactis vector.

Results published in the April 8, 2014, online edition of the American Journal of Gastroenterology revealed that elafin expression in the small intestinal epithelium was lower in patients with active CD compared with control patients. In vitro, elafin significantly slowed the kinetics of the deamidation of the 33-mer peptide to its more immunogenic form. Treatment of gluten-sensitive mice with elafin delivered by the L. lactis vector normalized inflammation and improved permeability.

Maintaining a gluten-free diet is far from simple, as gluten is found not only in foods but as low cost filler in the cosmetic and pharmaceutical industries as well.

“People who have to strictly avoid gluten for life often find this very difficult due to these hidden sources,” said senior author Dr. Elena Verdu, associate professor of medicine at McMaster University. “There is a great need for a therapy that will protect patients with celiac disease from these accidental contaminations. The possibility of elafin administration or replacement as a new adjuvant therapy to the gluten free diet would add flexibility to a restrictive lifelong diet, and increase patients’ quality of life and potentially accelerate the healing of celiac lesions.”

Related Links:

McMaster University



Print article

Channels

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.